Stay updated on IL-2 Combo for Refractory Checkpoint Blockade Clinical Trial
Sign up to get notified when there's something new on the IL-2 Combo for Refractory Checkpoint Blockade Clinical Trial page.

Latest updates to the IL-2 Combo for Refractory Checkpoint Blockade Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedThe web page has been updated to reflect a new version of a clinical study, with significant changes in the study's description and eligibility criteria. Notably, the addition of the treatment regimen and the removal of detailed eligibility criteria indicate a shift in focus towards the treatment approach.SummaryDifference57%
- Check30 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.1%
- Check37 days agoChange DetectedThe page has updated the status of a clinical trial to 'Unknown' and has changed the version from v2.14.2 to v2.14.3. Additionally, the last known status was confirmed as 'Recruiting' by Dr. Megan Daly from the University of California, Davis.SummaryDifference0.6%
- Check73 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference1%
- Check87 days agoChange DetectedThe page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference1%
Stay in the know with updates to IL-2 Combo for Refractory Checkpoint Blockade Clinical Trial
Enter your email address, and we'll notify you when there's something new on the IL-2 Combo for Refractory Checkpoint Blockade Clinical Trial page.